Mortality Is Not Increased in Recombinant Human Growth Hormone-treated Patients When Adjusting for Birth Characteristics
| Autor: | Lars Sävendahl, Aimon Niklasson, Anders Odén, Kerstin Albertsson-Wikland, Jan Gustafsson, Berit Kriström, Anton Mårtensson, Nils-Gunnar Pehrsson, Peter Fibiger Bang, Jovanna Dahlgren, Svante Norgren |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent Hormone Replacement Therapy Endocrinology Diabetes and Metabolism Birth weight Clinical Biochemistry Population 030209 endocrinology & metabolism Biochemistry Young Adult 03 medical and health sciences 0302 clinical medicine Endocrinology Cause of Death Internal medicine medicine Birth Weight Humans 030212 general & internal medicine Child education Growth Disorders Cause of death Sweden education.field_of_study Human Growth Hormone business.industry Biochemistry (medical) Infant Newborn Infant Models Theoretical medicine.disease Recombinant Proteins Confidence interval Idiopathic short stature Survival Rate Standardized mortality ratio Child Preschool Infant Small for Gestational Age IGHD Small for gestational age Female business |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 101:2149-2159 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jc.2015-3951 |
| Popis: | Objective: This study aimed to investigate whether reported high mortality in childhood recombinant human GH (rhGH)-treated patients was related to birth-characteristics and/or rhGH treatment. Design and Setting: We sought to develop a mortality model of the Swedish general population born between 1973 and 2010, using continuous-hazard functions adjusting for birth characteristics, sex, age intervals, and calendar year to estimate standardized mortality ratio (SMR) and to apply this model to assess expected deaths in Swedish rhGH-treated patients with idiopathic isolated GH deficiency (IGHD), idiopathic short stature (155) or born small for gestational age (SGA). Participants:The general population: Swedish Medical Birth Register (1973-2010: 1 880 668 males; 1 781 131 females) and Cause of Death Register (1985-2010). Intervention Population: Three thousand eight hundred forty-seven patients starting rhGH treatment between 1985 and 2010 and followed in the National GH Register and/or in rhGH trials diagnosed with IGHD (n = 1890), ISS (n = 975), or SGA (n=982). Main Outcome Measures: Death. Results: Using conventional models adjusting for age, sex, and calendar-year, the SMR was 1.43 (95% confidence interval, 0.89-2.19), P = .14, observed/expected deaths 21/14.68. The rhGH population differed (P < .001) from the general population regarding birth weight, birth length, and congenital malformations. Application of an Advanced Model: When applying the developed mortality model of the general population, the ratio of observed/expected deaths in rhGH-treated patients was 21/21.99; SMR = 0.955 (0.591-1.456)P = .95. Model Comparison: Expected number of deaths were 14.68 (14.35-14.96) using the conventional model, and 21.99 (21.24-22.81) using the advanced model, P < .001, which had at all ages a higher gradient of risk per SD of the model, 24% (range, 18-42%; P < .001). Conclusions: Compared with the general Swedish population, the ratio of observed/expected deaths (21/21.99) was not increased in childhood rhGH-treated IGHD, ISS, and SGA patients when applying an advanced sex-specific mortality model adjusting for birth characteristics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|